Reframing Value-Based Care: The Pivotal Role of Care Management

By Michael Awood

November 2, 2023

In the realm of healthcare, the concept of value-based care (VBC) is not new. Introduced by Michael Porter, VBC emphasises the importance of generating positive outcomes per unit of currency spent. Today, VBC is a driving force behind efforts to improve clinical outcomes while reducing costs. Central to this strategy is care management. This is designed to support selected patients via multidisciplinary teams to improve health-related outcomes.

The Role of Care Management in Value-Based Care

Care management programmes aim to assist with disease management, optimise care pathways through the healthcare system, and manage the utilisation of costs within the system. These programmes have encouraged participation by offering incentives, resulting in valuable data collection and improved efficiencies. However, despite these advances, patient-centred care is often overlooked in the current systems.

Understanding value in healthcare can be subjective. For some patients, value is about achieving personal health goals, even if these don’t translate into financial value for the health system. Fragmentation of care is also a notable challenge within these systems. It increases the complexity of patient care. With the entry of venture capitalists and other players into the healthcare system, effective care management has become essential for optimising performance and decreasing fragmentation.

A New Approach to Value-Based Care

The need for a patient-centred comprehensive care management continuum is becoming increasingly clear. This reframing of the VBC strategy consists of five key areas:

  1. Recognising that patients are multidimensional and their care trajectories fluctuate with their evolving health conditions;
  2. Offering a continuum of care management programming support matched to their specific needs;
  3. integrating and coordinating efforts to maximise resource utilisation;
  4. Committing to regular evaluation of broad program effectiveness;
  5. Redefining value from a person-centred and health equity-based perspective.

 

 

In line with the Just-In-Time (JIT) management philosophy, the concept of “the right program for the right patient” has emerged. This approach opens multiple access points for people to enter the system and offers various options for care. Patients are then graded to determine the level of care they need, from basic community health programmes to integrated care management for the most complex cases.

The Future of Care Management

Many innovation models require care management, and developers are creating alternative reimbursement models to promote comprehensive approaches. These models encourage care management for vulnerable populations and ensure rigorous evaluations by reviewing patient-centred outcomes. By introducing matrices for patient populations and attaching incentives, outcomes can improve.

Minimising the financial burden on patients and optimising the standard siloed approach to managed care are also key considerations. Multiple organisations can provide and coordinate care, but the proliferation of program offerings threatens to exacerbate the fragmentation of care delivery.

To promote patient-centred care management, health systems can benefit from providing a patient-tailored continuum of care management offerings. This would also provide an improved understanding of the care management ecosystem available to patients. Policymakers have a similar responsibility and opportunity to develop incentives to address worsening fragmentation in this field and to promote a more holistic, equitable, and patient-centred approach to care management aligned with value-based care.

As we move forward into the future of healthcare, the focus on value-based care and patient-centred care management will continue to shape the industry. The evolution of these concepts and their application in real-world settings will undoubtedly lead to improved patient outcomes and more efficient healthcare systems.

 

Image in text taken from the journal article linked below

Reference url

Recent Posts

MFN drug pricing
       

MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alignment

💡 Are U.S. and global drug prices set for a revolution?

The new Most-Favored-Nation (MFN) drug pricing policy from the HHS and CMS aims to align U.S. pharmaceutical prices with those in economically comparable countries, promising significant reductions without stifling innovation. This bold move could lead to more accessible medications for Americans while reshaping global pricing strategies.

Curious about how this might impact your commercial and pricing strategy? Dive into the details!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation #DrugPricing

HTA reform analysis
         

HTA Reform Analysis: Patterns and Global Trends in Health Technology Assessment

🌍 Ever wondered how health technology assessment (HTA) reforms shape global healthcare?

Our latest article provides a comprehensive analysis of HTA reforms across 14 international agencies, highlighting the evolving roles of “catalysts,” “traditionalists,” and “observers.” Discover how international collaborations are pivotal in advancing HTA methodologies and ensuring patient involvement in assessment processes.

Jump into the intricacies of HTA reforms and optimize your health economics strategies!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

drug pricing analysis
            

Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to Enhance Affordability in Pharma

💡 Are we paying too much for the medicines we need?

The Institute for Clinical and Economic Review (ICER) has released the protocol for its first annual “Launch Price and Access Report,” shedding light on the alarming rise of drug prices in the U.S. and the barriers patients face in accessing treatments. This comprehensive analysis not only explores price trends but also highlights the disconnect between drug pricing and its clinical value.

Dive into key findings that could shape the future of drug policy, affordability, and patient access.

Read the full article to discover more!

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.